HomeREGULATORY
REGULATORY

Kadcyla’s Premium Portion Cut by 90% on CEA, 1 Device Gets Upward Adjustment: Chuikyo
(Mar.8.2018)

Chugai Pharmaceutical’s cancer drug Kadcyla (trastuzumab emtansine) will be hit by a 90% reduction of its initial pricing premium in April based on evaluations under a pilot cost effective assessment (CEA) program, with its final NHI price trimmed by 1.5%, it was revealed on March 7 ...
(LOG IN FOR FULL STORY)